Other languages MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.86 ^USD	-1.38%		-7.74%	-50.69%

May. 09	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	May. 14
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	May. 09
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 09
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	Apr. 12
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	Apr. 11
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	Apr. 11
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	Apr. 10
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	Feb. 15
Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	Feb. 14
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	Feb. 13
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	Jan. 16
MEI Pharma : Change in Certifying Accountants - Form 8-K	Dec. 26
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	Dec. 14
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	Dec. 11
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	Dec. 11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Other languages

Filters